A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

Summary

This is a Phase 1/2, open-label study designed to investigate the safety, tolerability, PK, and anti-tumor activity of the study treatment in the treatment of patients with EGFR mutant NSCLC, who progressed following prior standard treatments which include the approved EGFR-TKIs with activity against T790M (e.g., osimertinib).

Timeline

Start

2024-06-14

Primary completion

2025-12-03

Completion

2025-12-03

Outcome

Outcome not reported

Stopped: “Sponsor's decision”

Drugs

Indications